- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 513/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
Patent holdings for IPC class C07D 513/22
Total number of patents in this class: 396
10-year publication summary
|
12
|
5
|
10
|
12
|
27
|
27
|
42
|
44
|
53
|
54
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Revolution Medicines, Inc. | 336 |
27 |
| Hoffmann-La Roche Inc. | 3818 |
16 |
| Vertex Pharmaceuticals Incorporated | 1579 |
15 |
| F. Hoffmann-La Roche AG | 7808 |
13 |
| Merck Patent GmbH | 5735 |
12 |
| Gilead Sciences, Inc. | 2236 |
12 |
| Hangzhou DAC Biotech Co., Ltd | 113 |
9 |
| Adlai Nortye Biopharma Co., Ltd. | 77 |
8 |
| Janssen Pharmaceutica N.V. | 3160 |
7 |
| Sumitomo Chemical Company, Limited | 8968 |
7 |
| Genzyme Corporation | 1382 |
7 |
| Sionna Therapeutics, Inc. | 30 |
7 |
| Raynergy Tek Inc. | 112 |
6 |
| Nuvalent, Inc. | 89 |
6 |
| Genfleet Therapeutics (Shanghai) Inc. | 70 |
5 |
| Adlai Nortye Pte. Ltd. | 14 |
5 |
| Bristol-myers Squibb Company | 4757 |
4 |
| Samsung Display Co., Ltd. | 38817 |
4 |
| Massachusetts Institute of Technology | 10282 |
4 |
| University of Sharjah | 61 |
4 |
| Other owners | 218 |